• Deferasirox Workflows for Ferroptosis Research

  2026-08-18

  Explore how Deferasirox can support controlled iron-metabolism experiments, from dose-response assays to mechanistic studies of ferroptosis resistance in hepatocellular carcinoma. The workflow emphasizes matched vehicle controls, oxygen-aware interpretation, and orthogonal validation rather than assuming that chelation alone predicts tumor-cell death.

• Estradiol–Autophagy Axis in Perimenopausal Aging

  2026-08-18

  The reference study integrates NHANES associations, network pharmacology, and perimenopausal mouse experiments to examine how declining estradiol relates to multi-organ aging. Its central contribution is evidence that estrogen receptor-dependent autophagy may connect hormone loss with fibrosis in the heart, aorta, and kidneys, while also defining important limits for translation to human hormone therapy.

• Dose- and Time-Dependent Ibotenic Acid Toxicity

  2026-08-17

  Dai and colleagues provide a systematic murine analysis showing that ibotenic acid toxicity depends strongly on both dose and elapsed time, combining behavioral observation with blood biochemistry, histopathology, and immunohistochemistry. The study identifies early c-fos activation and reduced Nissl bodies as useful indicators of neuronal stress or injury while defining important boundaries for interpreting ibotenic acid exposure in toxicology and neuroscience research.

• Purmorphamine: Smoothened Agonist Guide

  2026-08-17

  Purmorphamine is a synthetic Smoothened agonist used to activate Hedgehog signaling in osteogenic, stem-cell, neural, and sensory research. Product benchmarks report approximately 1 μM EC50 for alkaline phosphatase induction and approximately 1.5 μM IC50 for competitive BODIPY-cyclopamine binding to Smoothened.

• NU7441 (KU-57788): Reframing DNA-PK Translation

  2026-08-16

  NU7441 (KU-57788) is more than a DNA-PK inhibitor for sensitization studies. Its defined ATP-site mechanism offers a disciplined way to connect DNA repair research with cell-cycle phenotyping, oncology research, and emerging questions about cytosolic DNA and TDP-43 homeostasis. This article outlines a translational workflow while separating established evidence from forward-looking hypotheses.

• Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-08-15

  Lee and colleagues identified a new anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, led by compound 8c with an in vitro IC50 of 84 nM. The study combined medicinal chemistry, metabolic and pharmacokinetic profiling, docking, and mouse disease models to connect PDK4 inhibition with improved glucose tolerance, reduced allergic responses, and anticancer activity.

• Anti-Inflammatory Anti-Angiogenic Airway Stent

  2026-08-14

  Zhao et al. developed PAGL, an electrospun airway stent combining anlotinib hydrochloride with silver nanoparticles to address infection, inflammation, angiogenesis, and fibroblast activation in tracheal in-stent restenosis. The study supports a microenvironment-focused stent strategy, while its rabbit and transcriptomic data define important next steps rather than establishing clinical efficacy.

• MK 0893: Glucagon Receptor Antagonist Workflow

  2026-08-14

  MK 0893 enables a practical, mechanism-first workflow for measuring glucagon receptor binding, inhibition of cAMP production, and glucose-lowering activity. This guide connects nanomolar cell assays with hGCGR mouse studies while emphasizing solubility control, selectivity testing, and troubleshooting.

• Cyclic Pifithrin-α: A Translational p53 Lens

  2026-08-13

  Cyclic Pifithrin-α hydrobromide offers a reversible chemical approach to interrogating p53-dependent apoptosis, growth arrest, and DNA-damage responses. This thought-leadership perspective connects that biology with emerging neuroinflammatory mechanisms in trigeminal neuralgia while defining the evidence boundaries, experimental controls, and translational questions that should guide future work.

• Ruxolitinib, DRP1, and Pyroptosis in Anaplastic Thyroid Canc

  2026-08-13

  The 2024 Cell Death and Disease study identifies a mechanistic link between JAK1/2-STAT3 activity, DRP1-dependent mitochondrial fission, and two regulated cell-death programs in anaplastic thyroid carcinoma. Its findings position ruxolitinib as a useful experimental probe for studying JAK/STAT signaling pathway modulation and mitochondrial control of apoptosis and GSDME-mediated pyroptosis, while still requiring validation beyond current models.

• Dye Models for Small Tissue Biopsies in Pathology

  2026-08-12

  The reference study evaluated five dyes as pre-processing markers for small tissue biopsies and found that merbromin, hematoxylin, and Alcian blue improved tissue visibility. Hematoxylin was favored because it combined useful observability with lower toxicity and no apparent interference during routine slide examination.

• Pediatric ED Migraine Care: Sumatriptan Pathway

  2026-08-12

  A single-center retrospective study evaluated an emergency-department migraine pathway that placed intranasal sumatriptan early in treatment for patients aged 6 to 21 years. Pain scores improved substantially across the cohort, while intravenous access was associated with longer stays and higher charges, supporting further prospective evaluation of nonintravenous first-line care.

• Mycophenolic Acid in Whole-Blood Immunometabolism

  2026-08-11

  Mycophenolic acid provides a pathway-focused way to test how nucleotide metabolism shapes cytokine responses in standardized whole-blood assays. This practical guide combines an evidence-based workflow with stock-preparation guidance, assay controls, troubleshooting, and extensions for immunometabolic research.

• Pomalidomide (CC-4047): A Translational Strategy

  2026-08-11

  A genotype-aware framework for using Pomalidomide (CC-4047) in multiple myeloma and broader hematological malignancy research, linking tumor microenvironment modulation, cytokine biology, model selection, and erythroid progenitor cell differentiation to translational decision-making.

• SGI-1027 DNA Methyltransferase Inhibitor Workflows

  2026-08-10

  Build more informative cancer epigenetics experiments with SGI-1027 by pairing DNA methylation inhibition and tumor suppressor gene reactivation with time-resolved viability and cell-death measurements. This workflow helps distinguish cytostasis from killing while addressing solubility, dosing, and assay-interpretation challenges.

16270 records 1/1085 page Next 12345 下5页 Last page